Medications for Pulmonary Embolism
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Pulmonary Embolism.
Found 6 Approved Drugs for Pulmonary Embolism
Alteplase
Brand Names
Cathflo Activase, Activase
Alteplase
Brand Names
Cathflo Activase, Activase
Form: Injection, Kit
Method of administration: Intravenous
FDA approval date: November 13, 1987
Cathflo ® Activase ® (Alteplase) is indicated for the restoration of function to central venous access devices as assessed by the ability to withdraw blood.
Xarelto
Generic Name
Rivaroxaban
Xarelto
Generic Name
Rivaroxaban
Form: Tablet, Kit, Granule, For
Method of administration: Oral
FDA approval date: July 01, 2011
Classification: Factor Xa Inhibitor
XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation.
Apixaban
Brand Names
Eliquis 30-Day, Eliquis
Apixaban
Brand Names
Eliquis 30-Day, Eliquis
Form: Tablet, Kit
Method of administration: Oral
FDA approval date: December 28, 2012
Classification: Factor Xa Inhibitor
Apixaban tablet is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Arixtra
Generic Name
Fondaparinux
Arixtra
Generic Name
Fondaparinux
Form: Injection
Method of administration: Subcutaneous
FDA approval date: July 14, 2011
Classification: Factor Xa Inhibitor
ARIXTRA is a Factor Xa inhibitor (anticoagulant) indicated for: Prophylaxis of deep vein thrombosis (DVT) in adult patients undergoing hip fracture surgery (including extended prophylaxis), hip replacement surgery, knee replacement surgery, or abdominal surgery.
Dabigatran Etexilate
Brand Names
Pradaxa, Dabigatran
Dabigatran Etexilate
Brand Names
Pradaxa, Dabigatran
Form: Pellet, Capsule
Method of administration: Oral
FDA approval date: August 08, 2011
Classification: Direct Thrombin Inhibitor
Dabigatran etexilate capsules are direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation.
Showing 1-5 of 6
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances